Alphatec Holdings, Inc. (ATEC)

In our clinical practice evaluation, ATEC's trajectory is heavily supported by a 20% surge in surgical case volume and a 24% increase in surgeon users during Q2 2026. The integration of the InformatiX platform and EOS imaging technology is clearly driving higher surgeon utilization and deeper account penetration. When interviewing or assessing clinical adoption channels, the key metric to watch is whether these newly acquired surgeon users maintain high procedural volume and successfully transition to multi-product adoption across the spine portfolio.

On our desk, trading at just over 2x sales makes ATEC look exceptionally compelling relative to medical device peer multiples. The market is starting to reprice the name as free cash flow turns positive and leverage concerns ease. Management's discipline in keeping full-year revenue guidance at $882 million while lifting adjusted EBITDA guidance to $140 million signals tangible operating leverage. We are positioning long, treating the valuation discount as an attractive entry point for growth-oriented healthcare portfolios.

Watching the recent 5.9% stock pop after Q2 results, our risk management framework notes that while net losses narrowed to roughly $25.8 million on a GAAP basis, bottom-line profitability remains a work in progress. Furthermore, the recent $8.12 million shelf registration for 800,000 common shares tied to an ESOP program introduces minor dilution considerations. We are keeping a close eye on execution milestones regarding the JPMorgan credit facilities and overall balance sheet health.

As a hedge fund portfolio manager, the fundamental narrative for Alphatec has clearly shifted from a high-burn growth story to a maturing commercial operator. Achieving a non-GAAP net income of $11 million and a GAAP gross margin of 72.2% in Q2 demonstrates that scaling is finally hitting the income statement. If the company sustains this operational momentum and hits its elevated $140 million adjusted EBITDA target, multiple expansion could accelerate rapidly through the second half of 2026.

On our options desk, implied volatility has reacted favorably to the Q2 earnings beat, but we are utilizing out-of-the-money put spreads as a cost-effective hedge against potential broader market pullbacks in small-to-mid cap medtech equities. While ATEC's fundamentals are straightening out nicely—highlighted by $36 million in adjusted EBITDA and a 420 basis point expansion in EBITDA margin—maintaining downside protection is prudent given historical equity dilution and lingering GAAP net losses.

From a bio-analyst perspective, the core competitive advantage for ATEC lies in its tightly integrated procedural ecosystem. CEO Pat Miles emphasized that surgeons are not only joining the platform but doing more cases per user. To maintain this clinical momentum, the company must ensure its technical support and product availability keep pace with the 24% expansion in surgeon users. Any supply chain bottlenecks in high-demand spinal hardware lines could otherwise cap procedural growth.